Related Experiment Videos
Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects
Miguel Pocovi1, Fernando Civeira, Rodrigo Alonso
1Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain. mpocovi@unizar.es
Seminars in Vascular Medicine
|June 17, 2004
Summary
A Spanish program identifies familial hypercholesterolemia (FH) using genetic testing and family studies. This research identified 161 mutations, aiding international diagnosis and patient support.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol.
- Early identification and management of FH are crucial for preventing cardiovascular disease.
- A national case-finding program was established in Spain to address FH.
Purpose of the Study:
- To establish and optimize a comprehensive case-finding program for FH in Spain.
- To investigate the molecular basis of FH and genotype/phenotype correlations.
- To develop international guidelines for FH diagnosis and management.
Main Methods:
- Family-based investigations and molecular genetic testing for low-density lipoprotein receptor gene mutations.
- Development of a DNA-diagnostic platform including SSCP analysis, DNA sequencing, Southern blotting, and microarrays.
- Establishment of a patient organization for support and follow-up.
Main Results:
- Identification of 161 distinct mutations causing inherited hypercholesterolemia in Spanish FH patients.
- Construction of an optimized DNA-diagnostic platform for efficient mutation screening.
- Founding of a patient organization to enhance patient care and follow-up.
Conclusions:
- The Spanish FH case-finding program effectively utilizes genetic testing and family studies.
- The developed DNA-diagnostic platform facilitates high-throughput analysis and mutation identification.
- International guidelines are proposed to standardize FH diagnosis and clinical management, improving patient outcomes globally.